Analysis of Heme/Onc Drug Sensitivity Data

Join Notable Labs for an in-depth discussion on how data generated from a functional and multi-omic drug sensitivity screen for Acute Myeloid Leukemia (AML) can be harnessed for biomarker discovery, improved drug development and complement patient mutational data for more precise treatment strategies.

This webinar will highlight the integration of three technologies: a flow-cytometry drug sensitivity screen, DNA-Seq, and RNA-Seq. By augmenting a stand-alone drug sensitivity screen with multi-omic data, Notable Labs is amassing a continually-growing dataset that will provide utility for drug development and patient care in AML and other Heme/Onc indications.

Learn how this dataset, containing samples with matched drug sensitivity, gene expression, and variant data, enables researchers to look at the relationships between different data types in order to discover biomarkers, look at patient population stratification, and gain a deeper understanding of how drug sensitivity is influenced by genetics and gene expression.